ChiCTR2600126809 版本V1.0 版本创建时间2026/06/16 16:04:24 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600126809 

最近更新日期:

Date of Last Refreshed on:

2026-06-16 16:04:17 

注册时间:

Date of Registration:

2026-06-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同降脂药物对脂蛋白(a)浓度影响的大型多中心观察性研究

Public title:

Effects of Different Lipid-Lowering Agents on Lipoprotein(a) Levels: A Large Multicenter Observational Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同降脂药物对脂蛋白(a)浓度影响的大型多中心观察性研究

Scientific title:

Effects of Different Lipid-Lowering Agents on Lipoprotein(a) Levels: A Large Multicenter Observational Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张楠 

研究负责人:

展淑琴 

Applicant:

Nan Zhang 

Study leader:

Shuqin Zhan  

申请注册联系人电话:

Applicant telephone:

+86 187 9293 0805

研究负责人电话:

Study leader's
telephone:

+86 158 2929 2597

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

903357954@qq.com

研究负责人电子邮件:

Study leader's E-mail:

sqzhan@mail.xjtu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陕西省西安市西五路157号 西安交通大学第二附属医院

研究负责人通讯地址:

陕西省西安市西五路157号 西安交通大学第二附属医院

Applicant address:

The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xi Wu Road, Xi’an, Shaanxi, China

Study leader's address:

The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xi Wu Road, Xi’an, Shaanxi, China

申请注册联系人邮政编码:

Applicant postcode:

710004

研究负责人邮政编码:

Study leader's postcode:

710004

申请人所在单位:

西安交通大学第二附属医院

Applicant's institution:

The Second Affiliated Hospital of Xi'an Jiaotong University

研究负责人所在单位:

西安交通大学第二附属医院

Affiliation of the Leader:

The Second Affiliated Hospital of Xi'an Jiaotong University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2026)伦审-研第(095)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西安交通大学第二附属医院医学伦理委员会

Name of the ethic committee:

The medical ethics committee of the Second Affiliated Hospital of Xi'an Jiaotong University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-07 00:00:00

伦理委员会联系人:

王子明

Contact Name of the ethic committee:

ZiMing Wang

伦理委员会联系地址:

西安市新城区皇城西路30号

Contact Address of the ethic committee:

No. 30, Huangcheng West Road, Xincheng District, Xi'an

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 29 8767 8326

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

西安交通大学第二附属医院

Primary sponsor:

The Second Affiliated Hospital of Xi'an Jiaotong University

研究实施负责(组长)单位地址:

陕西省西安市西五路157号

Primary sponsor's address:

No. 157 Xi Wu Road, Xi’an, Shaanxi, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西省

市(区县):

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学第二附属医院

具体地址:

陕西省西安市西五路157号

Institution
hospital:

The Second Affiliated Hospital of Xi'an Jiaotong University

Address:

No. 157 Xi Wu Road, Xi’an, Shaanxi, China

经费或物资来源:

陕西省卫生健康科研项目

Source(s) of funding:

Foundation of Shaanxi health research project

研究疾病:

高脂血症  

Target disease:

Hyperlipidemia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究是一项前瞻性、多中心、大样本临床观察性研究,旨在通过此项研究,调查陕西地区在神经内科住院的Lp(a)升高患者中,Lp(a)的分布情况。并研究在急性脑梗死后,Lp(a)浓度的变化情况。明确不同降脂药物对Lp(a)浓度、复发缺血事件、颈动脉斑块的影响情况,为Lp(a)浓度升高患者的治疗决策提供循证医学依据。  

Objectives of Study:

This study is a prospective, multicenter, large-sample clinical observational study, aiming to investigate the distribution of Lp(a) in patients with elevated Lp(a) who are hospitalized in the Department of Neurology in the Shaanxi region. It also aims to study the changes in Lp(a) concentration after acute cerebral infarction, clarify the effects of different lipid-lowering drugs on Lp(a) concentration, recurrent ischemic events, and carotid plaques, and provide evidence-based medical guidance for treatment decisions in patients with elevated Lp(a) levels.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)Lp(a) ≥30 mg/dL 或≥ 75 mmol/L; (2)年龄在18-80岁之间; (3)受试者或法定代理人已被告知研究的性质,理解方案中的规定,能够保证依从性,并签署知情同意书。

Inclusion criteria

1. Lp(a) >= 30 mg/dL or >= 75 mmol/L; 2. Age between 18-80 years; 3. The subject or legal representative has been informed about the nature of the study, understands the provisions in the protocol, can ensure compliance, and has signed the informed consent form.

排除标准:

(1)慢性肾脏病(血肌酐>133 ummol/L或肾小球滤过率<60 mL/min/1.73 m2)、肝功能不全(转氨酶升高3倍以上)、恶性肿瘤患者; (2)患者可能对研究方案不依从(包括随访期),如精神异常、吸毒等。

Exclusion criteria:

1. Patients with chronic kidney disease (serum creatinine > 133 μmol/L or glomerular filtration rate < 60 mL/min/1.73 m^2), liver dysfunction (transaminase levels more than 3 times the normal), or malignant tumors; 2. Patients who may be non-compliant with the study protocol (including the follow-up period), such as those with mental disorders, drug abuse, etc.

研究实施时间:

Study execute time:

From 2026-07-01 00:00:00 To 2029-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-07-01 00:00:00 To 2028-07-01 00:00:00

干预措施:

Interventions:

组别:

PCSK9抑制剂组

样本量:

500

Group:

PCSK9 inhibitor group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

口服降脂药物组

样本量:

1500

Group:

Oral lipid-lowering drugs group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学第二附属医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Xi'an Jiaotong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Xi'an Jiaotong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

陕西省人民医院 

单位级别:

三甲 

Institution
hospital:

Shaanxi Provincial People’s Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

宝鸡市人民医院 

单位级别:

三甲 

Institution
hospital:

Baoji People’s Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

空军九八六医院 

单位级别:

三甲 

Institution
hospital:

The 986th Military Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安市中医医院 

单位级别:

三甲 

Institution
hospital:

Xi'an Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

商洛市中心医院 

单位级别:

三甲 

Institution
hospital:

Shangluo Center Hosipital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安市高新医院 

单位级别:

三甲 

Institution
hospital:

Xi'an Gaoxin Hosipital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安市中心医院 

单位级别:

三甲 

Institution
hospital:

Xi'an Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安医学院第一附属医院 

单位级别:

三甲 

Institution
hospital:

First Affiliated Hospital of Xi’an Medical College

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

空军军医大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Air Force Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

延安大学附属医院 

单位级别:

三甲 

Institution
hospital:

The Affiliated Hospital of Yan’an University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

脂蛋白(a)

指标类型:

主要指标

Outcome:

Lipoprotein(a)

Type:

Primary indicator

测量时间点:

入院时,出院后1、3、6、12个月

测量方法:

静脉采血,由各中心检验科测定

Measure time point of outcome:

At hospital admission, and at 1, 3, 6, and 12 months after discharge

Measure method:

Venous blood collection, measured by the laboratory of each center

指标中文名:

低密度脂蛋白

指标类型:

次要指标

Outcome:

low-density lipoprotein

Type:

Secondary indicator

测量时间点:

入院时,出院后1、3、6、12个月

测量方法:

静脉采血,由各中心检验科测定

Measure time point of outcome:

At hospital admission, and at 1, 3, 6, and 12 months after discharge

Measure method:

Venous blood collection, measured by the laboratory of each center

指标中文名:

甘油三酯

指标类型:

次要指标

Outcome:

Triglyceride

Type:

Secondary indicator

测量时间点:

入院时,出院后1、3、6、12个月

测量方法:

静脉采血,由各中心检验科测定

Measure time point of outcome:

At hospital admission, and at 1, 3, 6, and 12 months after discharge

Measure method:

Venous blood collection, measured by the laboratory of each center

指标中文名:

总胆固醇

指标类型:

次要指标

Outcome:

Total cholesterol

Type:

Secondary indicator

测量时间点:

入院时,出院后1、3、6、12个月

测量方法:

静脉采血,由各中心检验科测定

Measure time point of outcome:

At hospital admission, and at 1, 3, 6, and 12 months after discharge

Measure method:

Venous blood collection, measured by the laboratory of each center

指标中文名:

高密度脂蛋白

指标类型:

主要指标

Outcome:

High-density lipoprotein

Type:

Primary indicator

测量时间点:

入院时,出院后1、3、6、12个月

测量方法:

静脉采血,由各中心检验科测定

Measure time point of outcome:

At hospital admission, and at 1, 3, 6, and 12 months after discharge

Measure method:

Venous blood collection, measured by the laboratory of each center

指标中文名:

复发缺血事件

指标类型:

次要指标

Outcome:

Recurrent ischemic events

Type:

Secondary indicator

测量时间点:

随访过程中任一时间点

测量方法:

由随访人员进行询问,根据患者的住院记录得到

Measure time point of outcome:

At any time point during the follow-up

Measure method:

Inquired by follow-up personnel and obtained according to the patient's hospitalization records

指标中文名:

颈动脉斑块

指标类型:

次要指标

Outcome:

Carotid plaque

Type:

Secondary indicator

测量时间点:

入院时,出院后第12个月

测量方法:

颈部血管超声

Measure time point of outcome:

At admission, 12 months after discharge

Measure method:

Neck vascular ultrasound

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用纸质病例报告表(CRF)及电子采集和管理系统(EDC)进行数据采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is conducted using paper Case Report Forms (CRFs) and an Electronic Data Capture and Management System (EDC).

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-06-16 16:04:17